Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALM201 in Advanced Solid Tumours and Ovarian Cancer
NCT03427073Phase 1Terminated
- Sponsor
- Almac Discovery
- Start
- Apr 2015
- Primary completion
- Mar 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of ALM201 in solid tumor and ovarian cancer (2 arms), sponsored by Almac Discovery. Primary endpoint: Safety and Tolerability - Evaluation of AEs and DLT. Started Apr 2015; status: terminated.
02
Drugs
ALM201
03
Conditions
solid tumorovarian cancer
Beyond the preview
Go deeper on NCT03427073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03427073.